Vera Therapeutics (VERA) Stock Price, News & Analysis

Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $21.68 to $22.65
• 50-Day Range: $19.25 to $24.35
• 52-Week Range: $18.53 to $51.61
• Volume: 1.50 million shs
• Average Volume: 1.33 million shs
• Market Capitalization: $1.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Moderate Buy

Vera Therapeutics Stock Analysis - MarketRank™

Vera Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 246th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vera Therapeutics is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vera Therapeutics is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vera Therapeutics has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.87% of the float of Vera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vera Therapeutics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Vera Therapeutics has recently decreased by 8.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vera Therapeutics does not currently pay a dividend.

Dividend Growth

Vera Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.87% of the float of Vera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vera Therapeutics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Vera Therapeutics has recently decreased by 8.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.16

News Sentiment

Vera Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Vera Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Vera Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,277,598.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.30% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERA Stock Analysis - Frequently Asked Questions

How have VERA shares performed this year?

Vera Therapeutics' stock was trading at $42.29 at the beginning of the year. Since then, VERA shares have decreased by 47.9% and is now trading at $22.02.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) issued its earnings results on Tuesday, August, 5th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.38.

When did Vera Therapeutics IPO?

Vera Therapeutics (VERA) raised $66 million in an IPO on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

Who are Vera Therapeutics' major shareholders?

Vera Therapeutics' top institutional shareholders include Vestal Point Capital LP (4.86%), Geode Capital Management LLC (2.03%), Commodore Capital LP (1.25%) and American Century Companies Inc. (1.12%). Insiders that own company stock include Commodore Capital Lp, Patrick G Enright, Sofinnova Venture Partners X,, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Joanne Curley and Celia Lin.
View institutional ownership trends.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/27/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VERA
• CIK: 1831828
• Web: veratx.com
• Phone: 650-770-0077
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vera Therapeutics: $63.00
• High Price Target: $100.00
• Low Price Target: $26.00
• Potential Upside/Downside: +187.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$152.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.70%
• Return on Assets: -39.46%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 17.03
• Quick Ratio: 17.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.34 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 63,820,000
• Free Float: 53,421,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 1.17